Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tauopathies Clear all
Terminated Phase 3 Interventional Results available

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT05026177
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 87 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 25, 2026, 2:51 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Preventing Alzheimer's With Cognitive Training

NCT03848312
View directory record Official record
Conditions
Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias
Interventions
Cognitive Training, Computerized Cognitive Stimulation
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
65 Years and older
Enrollment
7,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
7
States / cities
Gainesville, Florida • Jacksonville, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

NCT01447719
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking

NCT03919669
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
All Subjects
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline

NCT02921672
View directory record Official record
Conditions
Alzheimer's Disease, Cognitive Impairment
Interventions
Mediterranean Diet
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Tau Screening Study in Subjects With Early Symptomatic AD

NCT03467477
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Irvine, California • Delray Beach, Florida • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 25, 2026, 2:51 AM EDT
Not listed Phase 2 Interventional

Phase II Clinical Trial of Interleukin-2 in AD

NCT06096090
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interleukin-2, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Sep 25, 2026, 2:51 AM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

NCT03919162
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PQ912, Placebo
Drug · Other
Lead sponsor
Vivoryon Therapeutics N.V.
Industry
Eligibility
50 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 25, 2026, 2:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II

NCT00059410
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Association
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 25, 2026, 2:51 AM EDT
Terminated Phase 3 Interventional Results available

Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers

NCT00550420
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone XR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
51 Years to 91 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Palo Alto, California • Deerfield Beach, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

NCT02788513
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Colton, California • Long Beach, California • Redlands, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

NCT04070378
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Daratumumab Injection
Drug
Lead sponsor
Marc L Gordon, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

NCT00594568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY450139, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
1,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

NCT03838185
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
J147, Placebo
Drug
Lead sponsor
Abrexa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 25, 2026, 2:51 AM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)

NCT03354143
View directory record Official record
Conditions
Hypertension
Interventions
Standard Care, Intensive Treatment
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

NCT00506415
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 25, 2026, 2:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Reducing Dementia Risk With Digital Health Coaching

NCT04559789
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Cognitive Decline
Interventions
MindMate + Health Coaching, Health Education
Behavioral · Other
Lead sponsor
Neurotrack Technologies, Inc.
Industry
Eligibility
45 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Memory in Mild Cognitive Impairment and Early Stage Alzheimer's Disease

NCT05077826
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
North Coast Medical Activadose II
Device
Lead sponsor
The Mind Research Network
Other
Eligibility
50 Years to 90 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 25, 2026, 2:51 AM EDT
Active, not recruiting Not applicable Interventional

Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease

NCT04055376
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia
Interventions
GENUS device (Active Settings), GENUS device (Sham Settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
50 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440
View directory record Official record
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 25, 2026, 2:51 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Phoenix, Arizona • Imperial, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 25, 2026, 2:51 AM EDT
Completed Not applicable Interventional Results available

Mild Cognitive Impairment and Obstructive Sleep Apnea

NCT01482351
View directory record Official record
Conditions
Obstructive Sleep Apnea, Mild Cognitive Impairment
Interventions
CPAP adherence intervention, Attention control intervention
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
55 Years to 89 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Abington, Pennsylvania • Philadelphia, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 25, 2026, 2:51 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Study of Caregiver Connections Via Technology in Dementia

NCT05779839
View directory record Official record
Conditions
Caregiver Stress, Dementia, Alzheimer Disease, Lewy Body Dementia, Parkinson Disease Dementia, Frontotemporal Dementia
Interventions
Algorithm, Random Match
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 25, 2026, 2:51 AM EDT